tyrosyl-prolyl-tryptophyl-glycinamide and beta-funaltrexamine

tyrosyl-prolyl-tryptophyl-glycinamide has been researched along with beta-funaltrexamine in 2 studies

Compound Research Comparison

Studies (tyrosyl-prolyl-tryptophyl-glycinamide)	Trials (tyrosyl-prolyl-tryptophyl-glycinamide)	Recent Studies (post-2010) (tyrosyl-prolyl-tryptophyl-glycinamide)	Studies (beta-funaltrexamine)	Trials (beta-funaltrexamine)	Recent Studies (post-2010) (beta-funaltrexamine)
25	0	0	542	1	54

Protein Interaction Comparison

Protein	Taxonomy	beta-funaltrexamine (IC50)
Muscarinic acetylcholine receptor M2	Rattus norvegicus (Norway rat)	0.082
Prostaglandin G/H synthase 1	Homo sapiens (human)	0.082
Delta-type opioid receptor	Mus musculus (house mouse)	0.082
Kappa-type opioid receptor	Mus musculus (house mouse)	0.082
Mu-type opioid receptor	Mus musculus (house mouse)	0.082

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gergen, KA; Kastin, AJ; Paul, D; Zadina, JE	1
Fujimura, T; Ito, K; Kawamura, S; Mizoguchi, H; Murayama, K; Nakayama, D; Sakurada, C; Sakurada, S; Sakurada, T; Sato, T; Watanabe, C; Watanabe, H	1

Other Studies

2 other study(ies) available for tyrosyl-prolyl-tryptophyl-glycinamide and beta-funaltrexamine

Article	Year
Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors. European journal of pharmacology, 1996, Mar-18, Volume: 298, Issue:3 Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amino Acid Sequence; Animals; Desipramine; Dose-Response Relationship, Drug; Injections, Spinal; Male; Mice; Molecular Sequence Data; MSH Release-Inhibiting Hormone; Naloxone; Naltrexone; Narcotic Antagonists; Norepinephrine; Receptors, Adrenergic, alpha-2; Yohimbine	1996
A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective mu2-opioid receptor antagonist in the mouse. The Journal of pharmacology and experimental therapeutics, 2005, Volume: 312, Issue:3 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Animals; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Male; Mice; MSH Release-Inhibiting Hormone; Naloxone; Naltrexone; Narcotic Antagonists; Oligopeptides; Receptors, Opioid, mu	2005

Article

Year

Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors.

European journal of pharmacology, 1996, Mar-18, Volume: 298, Issue:3

Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amino Acid Sequence; Animals; Desipramine; Dose-Response Relationship, Drug; Injections, Spinal; Male; Mice; Molecular Sequence Data; MSH Release-Inhibiting Hormone; Naloxone; Naltrexone; Narcotic Antagonists; Norepinephrine; Receptors, Adrenergic, alpha-2; Yohimbine

1996

A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective mu2-opioid receptor antagonist in the mouse.

The Journal of pharmacology and experimental therapeutics, 2005, Volume: 312, Issue:3

Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Animals; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Male; Mice; MSH Release-Inhibiting Hormone; Naloxone; Naltrexone; Narcotic Antagonists; Oligopeptides; Receptors, Opioid, mu

2005